Market Overview

UPDATE: Cantor Fitzgerald Initiates Catamaran at Buy on Growth Outlook

UPDATE: Morgan Stanley Reiterates Equal-Weight Rating on Catamaran Corp Following Salveo Acquisition
Catamaran To acquire Salveo Specialty Pharmacy For $260M In Cash

Cantor Fitzgerald initiated coverage on Catamaran (NASDAQ: CTRX) with a Buy rating and a $56 price target.

Cantor Fitzgerald noted, "The favourable market drivers for the industry include: 1) increased drug utilization; 2) aging population; 3) growth of chronic diseases; and 4) drug price inflation. Catamaran is poised to benefit from the disruption associated with the Express Scripts merger with Medco Health. Major margin drivers for the PBMs are: the increase usage of generic prescription drugs; increased spending on specialty drugs; increased mail and gross margin leverage with scale."

Catamaran closed at $48.56 on Tuesday.

Latest Ratings for CTRX

Mar 2015Mizuho SecuritiesInitiates Coverage onBuy
Feb 2015Deutsche BankMaintainsHold
Feb 2015Leerink SwannMaintainsOutperform

View More Analyst Ratings for CTRX
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Initiation Pre-Market Outlook Analyst Ratings


Related Articles (CTRX)

Around the Web, We're Loving...